ReviewAmerican journal of physiology. Lung cellular and molecular physiology2008
Pulmonary applications and toxicity of engineered nanoparticles.
Review in American journal of physiology. Lung cellular and molecular physiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 304 citations in OpenAlex.
- Green Nanomedicine from Eupatorium: Phytochemical-Driven Synthesis of Therapeutic Nanoparticles for Biomedical Applications.Applied biochemistry and biotechnology · 2026Review
- Predictive Screening of TaACS nano · 2026Article
- Lipid Nanoparticle-Mediated Antifungal and Immunomodulatory Therapy for Neuromycoses.International journal of nanomedicine · 2026Review
- Inhalable Nanotechnology-Based Drug Delivery Systems for the Treatment of Inflammatory Lung Diseases.Pharmaceutics · 2025Review
- Nanotechnology in healthcare, and its safety and environmental risks.Journal of nanobiotechnology · 2024Review
- Nanotechnology-based approaches for targeted drug delivery for the treatment of respiratory tract infections.Journal of biological methods · 2024Review
- Inhalation exposure-induced toxicity and disease mediated via mTOR dysregulation.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects.Journal of nanobiotechnology · 2023Review
- Recent advances of nanotechnology in COVID 19: A critical review and future perspective.OpenNano · 2023Review
- Review
- Fluorescent PLGA Nanocarriers for Pulmonary Administration: Influence of the Surface Charge.Pharmaceutics · 2022Article
- MicroRNA Targets for Asthma Therapy.Advances in experimental medicine and biology · 2021Article
- Long-term exposure to a mixture of industrial SOEnvironmental health : a global access science source · 2020Article
- Simulation of nanoparticle transport and adsorption in a microfluidic lung-on-a-chip device.Biomicrofluidics · 2020Article
- Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- A novel human 3D lung microtissue model for nanoparticle-induced cell-matrix alterations.Particle and fibre toxicology · 2019Article
- A 3D human lung-on-a-chip model for nanotoxicity testing.Toxicology research · 2018Article
- Ten Things You Might Not Know about Iron Oxide Nanoparticles.Radiology · 2017Review
- Biological Fate of Fe₃O₄ Core-Shell Mesoporous Silica Nanoparticles Depending on Particle Surface Chemistry.Nanomaterials (Basel, Switzerland) · 2017Article
- Low dose inflammatory potential of silica particles in human-derived THP-1 macrophage cell culture studies - Mechanism and effects of particle size and iron.Chemico-biological interactions · 2017Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Because of their unique physicochemical properties, engineered nanoparticles have the potential to significantly impact respiratory research and medicine by means of improving imaging capability and drug delivery, among other applications. These same properties, however, present potential safety concerns, and there is accumulating evidence to suggest that nanoparticles may exert adverse effects on pulmonary structure and function. The respiratory system is susceptible to injury resulting from inhalation of gases, aerosols, and particles, and also from systemic delivery of drugs, chemicals, and other compounds to the lungs via direct cardiac output to the pulmonary arteries. As such, it is a prime target for the possible toxic effects of engineered nanoparticles. The purpose of this article is to provide an overview of the potential usefulness of nanoparticles and nanotechnology in respiratory research and medicine and to highlight important issues and recent data pertaining to nanoparticle-related pulmonary toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.